<DOC>
	<DOCNO>NCT01727232</DOCNO>
	<brief_summary>The aim large French multicentric retrospective study compare efficacy safety two ( standard Rheumatoid arthritis ) rituximab regimens adult 's immune thrombocytopenia .</brief_summary>
	<brief_title>Efficacy Safety Rituximab Given Fixed Dose ( 1000 mg Days 1 15 ) Compared Standard Regimen Adult 's Immune Thrombocytopenia</brief_title>
	<detailed_description>Every adult ( age â‰¥ 18 year ) see one 3 participate centre ( dijon , Marseille , Mondor ) 7-year period ( 2005-2012 ) definite diagnosis primary ITP accord American Society Hematology guideline receive RTX regardless regimen could include .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Primary ITP Age &gt; 18 year Secondary ITP Age &lt; 18 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>ITP</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Anti-CD20</keyword>
	<keyword>Regimen</keyword>
</DOC>